423-637-6991 [email protected]

Developing Tomorrow’s Medical Breakthrough Technologies Today

Our Mission

Supporting high impact Neuroscience research initiatives with Foundation staff and laboratory resources; and by grant awards to outstanding scientists engaged in biomedical studies at facilities in the US and overseas.

The Foundation Research Advisors are led by its President and Medical Director, Thomas Devlin, MD, PhD. Current priority areas of interest are stroke and Alzheimer’s Disease. Healthcare Economics is another area of study. 

In addition to a research Mission, the Foundation supports professional medical education and lecture programs by outstanding research scientists and clinicians. Another key aspect of the Foundation Mission Statement is the encouragement of Jobs and Community economic development by facilitating the creation of urban biotech districts. And finally, the Foundation also provides grants for hospitals to purchase advanced medical equipment for their Neurology service lines.

Home

A Message from Our President

and Chief Medical Officer

Toms Signature

Thomas G. Devlin, MD, PhD

President and Chief Medical Officer

NeuroScience Innovation Foundation

Greetings and Welcome

Please join me and my colleagues at the NeuroScience Innovation Foundation in advancing frontiers of medicine. It’s very exciting for all of us to have launched the Foundation in late 2020 and for donors to have stepped forward to fund initial projects.

Stroke is an area of early interest with Alzheimer’s dementia emerging as a pathology where new disease models based on brilliant neurobiology may, at long last, offer some crucial breakthroughs.

Projects and research the Foundation is looking to initiate in the Neuroscience arena are diverse in scope.

VALIDATE: The Largest Study of its Kind

Assessing the impact of artificial intelligence (AI)-based medical technology was conceived by Dr. Thomas Devlin, Medical Director of the NeuroScience Innovation Foundation. 

VIZai

The key finding from VALIDATE is that that a

AI-based cell-phone app called VIZ.ai, reduces the time it takes for a patient to be diagnosed with an ischemic stroke by 44%

compared to cases where an AI product was not used. That comparative advantage translates into much faster “time to treatment” in a stroke emergency, and this often results in greatly enhanced medical outcomes.

Home

The 2025 Foundation Research Agenda includes these items

Post-Photo-Alzheimers

Alzheimers and Dementia Research

The NeuroScience Innovation Foundation has been very active in supporting exciting  Alzheimer’s and Dementia Research.

Music_therapy

Music Therapy Research

to hasten and advance recovery from neurologic disease.

Lab

The Lab

to design and test stroke intervention devices.

Healthcare-Economics

Healthcare Economics

studies on stroke therapies performed in collaboration with local academics.

NSIF_ Chat

Chattanooga Bio-Tech Strategic Planning and Community Development

to route patients to appropriate levels of emergency intervention care.

.

Seminar

National and Regional Professional Education

events for physicians and nurses.

Precision

Center for Precision Medicine

This is a brand new discipline that designs medical therapies tailored to individual genetic and personal history. We’ve gathered a team of local experts to evaluate and help implement Precision Medicine programs..

Gifted (1)

Targeted Gifts for Clinical Care

tele-medicine equipment, stroke nurse training and video streaming systems.

Meet Our Officers

THOMAS DEVLIN MD, PhD

THOMAS DEVLIN MD, PhD

President and Medical Director

 

Dr. Thomas Devlin is world-renowned for his research in acute ischemic stroke with over twenty years of experience as a vascular neurologist Currently, he is the Director of the Chattanooga-based CHI–Memorial Stroke & Neuroscience Center, part of the national organization Common Spirit.

Prior to his CHI-Memorial appointment Dr. Devlin served as the Chairman of the Department of Neurology for over 10 years at the University of Tennessee College of Medicine, Chattanooga, and is currently on faculty there as a full professor of Neurology.

As the Neurology Department Chair and Medical Director of the Clinical Program at Erlanger Health System, Dr. Devlin recruited a team of eminent stroke Neurologists and Interventional Radiologists becoming one of the largest and most highly respected stroke treatment facilities worldwide.

He is the Founder and Director of the Chattanooga Center for Neurologic Research (CCNR), a private research company, serving as well as the President and Medical Director of the NeuroScience Innovation Foundation.  As the director of CCNR, Dr. Devlin has published more than a dozen articles on acute stroke treatment and with Dr. Blaise Baxter, he authored the first single-center confirmation of the clinical benefit of advanced stroke thrombectomy procedures using the MERCI device. His center was the highest enrolling center and the center demonstrating the very best patient outcomes worldwide in the landmark SWIFT-PRIME study that proved the benefit of endovascular therapy for stroke over IV tPA.

As the director of the Chattanooga Center for Neurologic Research, Dr. Devlin has developed Erlanger hospital into a testbed center for translational research for high-tech, cutting-edge, stroke treatments in partnership with biotech companies from around the world. Dr. Devlin has been a Principal Investigator on over 60 major clinical trials of new thrombolytic, neuroprotectant, stem-cell, and device therapies for acute stroke. He currently serves as the national principal investigator for the LUMOSA trial of a novel thrombolytic medication. In partnership with Dr. Peter Hunt, an otolaryngologist from Chattanooga, he helped pioneer the use of the Brainsgate surgical device, and its telemedicine-based navigation system, for intracranial arterial dilation in acute stroke patients. And as the director of the leading American site in the Brainsgate trial, the technology is now pending full FDA approval. More recently, Dr. Devlin has been instrumental in the FDA approval of two new artificial intelligence-based technologies: Viz.ai and NovaSignal. Dr. Devlin was the lead clinician in the development of these technologies and his center was the first hospital to acquire both technologies once fully commercialized. He is now the national principal investigator on the DISTINCTION trial designed to prove the clinical benefit of Viz.ai.

Dr. Devlin is founder and currently the Medical Director of the Neuroscience Innovation Foundation, a medical nonprofit corporation supporting research and clinical care in Neuroscience.

Previously, Dr. Devlin was the Founder of the non-profit Pleiades Foundation for Advanced Neuro-Medical Education which provided medical education to physicians and administrators throughout the world on both the clinical and financial aspects of stroke center development. The activities of the Pleiades Foundation were assumed by Erlanger Health System in 2016.

Dr. Devlin served as the National Program Co-Chair of the International Society for Vascular and Interventional Neurology in 2017 and 2018 and was awarded a fellowship from that society.

Thomas Devlin earned his medical degree from Baylor College of Medicine in 1991, completed a residency in Neurology at Duke University in 1995, and a fellowship in neurocritical care at the University of Virginia in 1996 with the father of neurocritical care, Dr. Thomas Bleck.

PETER CATALANO

PETER CATALANO

Treasurer/ CEO

Peter Catalano has collaborated with Dr. Devlin for many years. Prior to founding the NeuroScience Innovation with Devlin, Peter was CEO of the Pleiades Foundation, a non-profit corporation the provided advanced neuromedical education to an international audience of physicians and hospital administrators. Over the years, the Pleaides enrolled more than 700 attendees to study Stroke Neurointerventional medical procedures and Stroke Center Operations and Finances. Peter Catalano played a pivotal role in forging cooperative relations between medical clinicians and industry innovators. Earlier in his career Peter worked on advanced engineering research into robot-based assembly systems at MIT-affiliated Charles Stark Draper Laboratories in Cambridge, MA. For several years Peter was also a science journalist covering everything from astrophysics to theoretical biology and hurricane forecasting. Peter is a graduate of Columbia College in New York City majoring in Economics with a minor degree in Philosophy.

MARTHA SUMMA-CHADWICK, DMA

MARTHA SUMMA-CHADWICK, DMA

Research Associate/ Music Therapy

 

Martha Summa-Chadwick, DMA has achieved a national reputation as an educator, presenter, performer, and advocate for the cause of music in therapy. 
Martha has performed as piano and harpsichord soloist with orchestras across the country and served for twenty-six years on the faculty of the Cadek Conservatory in Chattanooga, Tennessee.  For the past two decades, Dr. Summa-Chadwick has explored various ways to use music for therapeutic as well as aesthetic ends.  Martha is the Executive Director of the nonprofit organization Music Therapy Gateway in Communications, Inc., and a frequent guest speaker at both national and regional conferences, discussing the use of biomedical music techniques for challenged children.
Martha has given two TED talks and established a series of both chamber and solo concerts to help educate diverse audiences in an overview of biomedical music protocols, and how music can be used in collaboration with improved neural learning patterns. She is also exploring how biomedical music protocols could be automated into software applications for persons with motor, speech, or cognition challenges.
DAVID PORTER

DAVID PORTER

Corporate Secretary

David Porter has worked for almost two decades in the field of visual merchandising as both a designer and engineer. He is currently director of engineering for the health & beauty division at Marketing Alliance Group in Dalton, GA. His client facing role involves proving design and manufacturing solutions for retailers Sephora and Ulta Beauty as well as over a dozen prestige cosmetic brands. Over the years he has worked with a wide array of Fortune 500 retailers in the grocery, convenient and department store environments. David is a graduate of the University of Michigan with a major in Industrial Design and a minor in Art History.

Contact Us

Developing Tomorrow’s Medical Breakthrough Technologies Today

423-637-6991

725 Glenwood Drive,
Rm E 880-A
Chattanooga, TN 37404

© NeuroScience Innovation Foundation 2023

web design by Mark Devlin Visual Design  www.md-visualdesign.com